The Role of Functional Imaging in Colorectal Cancer

Figueiras, R. García; Goh, Vicky; Padhani, Anwar R.; Naveira, Alberto; Caamaño, Antonio Gómez; Martín, Carmen

doi:10.2214/ajr.10.4422

Cited by 53 publications

(39 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, the similar results reflect the robustness of ΔSUV for assessment of treatment response (3,6). Nevertheless, the 2 sets of criteria differ in several aspects.…”

Section: Discussionsupporting

confidence: 55%

“…For several malignancies, including colorectal cancer, 18 F-FDG PET/CT examination is today recommended for preoperative staging and detection of recurrence (3)(4)(5)(6), and there is growing research attention to expanding the use of 18 F-FDG PET/CT in evaluating the response of metastatic disease (7)(8)(9)(10). To create the reproducibility that is needed for comparison of response rates between trials, the use of 18 F-FDG PET/CT in the setting of metastatic disease requires a fundamental standardization and consensus on response quantification methodology (11)(12)(13).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab

et al. 2013

View full text Add to dashboard Cite

The study aim was to compare European Organization for Research and Treatment of Cancer (EORTC) criteria with PET Response Criteria in Solid Tumors (PERCIST) for response evaluation of patients with metastatic colorectal cancer treated with a combination of the chemotherapeutic drug irinotecan and the monoclonal antibody cetuximab. Methods: From 2006 to 2009, patients with metastatic colorectal cancer were prospectively included in a phase II trial evaluating the combination of irinotecan and cetuximab every second week, as third-line treatment. 18 F-FDG PET/CT was performed between 1 and 14 d before the first treatment and after every fourth treatment cycle until progression was identified by CT with Response Evaluation Criteria in Solid Tumors (RECIST). Response evaluation with 18 F-FDG PET/CT was retrospectively performed according to both EORTC criteria and PERCIST, classifying the patients into 4 response categories: complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease (PMD). Individual best overall metabolic response (BOmR) was registered with both sets of criteria, as well as survival within response categories, and compared. Results: A total of 61 patients and 203 PET/CT scans were eligible for response evaluation. With EORTC criteria, 38 had PMR, 16 had SMD, and 7 had PMD as their BOmR. With PERCIST, 34 had PMR, 20 had SMD, and 7 had PMD as their BOmR. None of the patients had CMR. There was agreement between EORTC criteria and PERCIST in 87% of the patients, and the corresponding k-coefficient was 0.76. Disagreements were confined to PMR and SMD. Median overall survival (OS) in months with EORTC criteria was 14.2 in the PMR group and 7.2 in the combined SMD 1 PMD group. With PERCIST, it was 14.5 in the PMR group and 7.9 in the SMD 1 PMD group. Conclusion: Response evaluation with EORTC criteria and PERCIST gave similar responses and OS outcomes with good agreement on BOmR (k-coefficient, 0.76) and similar significant differences in median OS between response groups. Compared with EORTC criteria, we find PERCIST unambiguous because of clear definitions and therefore more straightforward to use.

show abstract

“…Additionally, the similar results reflect the robustness of ΔSUV for assessment of treatment response (3,6). Nevertheless, the 2 sets of criteria differ in several aspects.…”

Section: Discussionsupporting

confidence: 55%

mentioning

confidence: 99%

Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Second, although DCE-MRI is a noninvasive and sensitive technique for quantifying the physiology of tumor tissues, the acquisition protocols are far from uniform. Especially, semiquantitative data which analyze signal intensity changes were not readily transferable between different centers due to different machine set-up characteristics (37,39). Therefore, comparison of studies from different groups is complicated and may result in an underestimation of the ability of DCE-MRI.…”

Section: Discussionmentioning

confidence: 99%

Dynamic contrast‐enhanced MRI of primary rectal cancer: Quantitative correlation with positron emission tomography/computed tomography

Khong

Wang

et al. 2011

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Purpose: To assess the correlations between parameters measured on dynamic contrast-enhanced magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in rectal cancer. Materials and Methods:To assess the correlations between parameters measured on dynamic contrastenhanced MRI and FDG-PET in rectal cancer.Results: Significant correlations were only demonstrated between k ep and SUVmax (r ¼ 0.587, P ¼ 0.001), and k ep and SUVmean (r ¼ 0.562, P ¼ 0.002). No significant differences were found in imaging parameters between well, moderately and poorly differentiated adenocarcinoma groups. However, there was a trend that higher imaging values were found in poorly differentiated adenocarcinomas. Conclusion:Positive correlations were found between k ep and SUV values in primary rectal adenocarcinomas suggesting an association between angiogenesis and metabolic activity and further reflecting that angiogenic activity in washout phase is better associated with tumor metabolism than the uptake phase.

show abstract

“…Ultrasonography (US) shows circumferential, symmetric, homogeneous, hypoechoic thickening of colon. MDCT images show marked wall thickening of the colon, and rectum with pericolonic stranding [13]. MRI and positron emission tomography-CT (PET-CT) are the other imaging modalities used in the diagnosis of IBD and CC.…”

Section: Resultsmentioning

confidence: 99%

The utility of diffusion-weighted magnetic resonance imaging in differentiation of benign and malignant diffuse colon wall thickening

Koç¹,

Serhatlioğlu²

2017

Med-Science

View full text Add to dashboard Cite

To examine the effectiveness of apparent diffusion coefficient (ADC) values in differentiation of benign bowel wall thickening and malignant diffuse scirrhous type's bowel wall thickening. Subject and Methods A total of 81 patients who underwent abdomen diffusion-weighted magnetic resonance imaging (DW MRI) in our clinic between April 2015 and September 2016 was analyzed. Of these patients, 42 had benign bowel wall thickening and 39 had malignant bowel wall thickening. The values of ADC were measured with two different b-values (400, 1000 s/mm2). Benign and malignant ADC values were compared using areas under the receiver-operating characteristic (ROC) curve. Results: According to the ADC values, the mean ADC values (x10-3 mm2/s) of benign lesions were 1.42±0.17 for b 400, 1.39±0.12 for b 1000. The mean ADC values (x10-3 mm2/s) of malignant lesions were 1.08±0.15 for b 400, 1.02±0.13 for b 1000. There were significantly lower ADC values in malignant lesions in all b values (P=.001 for b 400, P=.001 for b 1000). ROC analysis showed that a cut-off value of 1.24 x 10-3 mm2/s between the malignant and benign values with a sensitivity of 91 %, specificity of 85 %, and an accuracy of 84 %. The positive predictive value, negative predictive value, and diagnostic accuracy of ADC values were determined to be 97 %, 86 %, and 88 % respectively. Conclusion: Measurement of ADC values by DWI was effective in differentiation of malignant diffuse scirrhous types of bowel wall thickening from benign bowel wall thickening.

show abstract

The Role of Functional Imaging in Colorectal Cancer

Abstract: Functional imaging now has a growing role in colorectal cancer. Recent developments in imaging technologies and validation of these newer imaging techniques may lead to significant improvements in the management of patients with colorectal cancer.

Cited by 53 publications

References 79 publications

Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab

Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab

Dynamic contrast‐enhanced MRI of primary rectal cancer: Quantitative correlation with positron emission tomography/computed tomography

The utility of diffusion-weighted magnetic resonance imaging in differentiation of benign and malignant diffuse colon wall thickening

Contact Info

Product

Resources

About